**Let-7d and miR-185 Impede Epithelial-Mesenchymal Transition by Downregulating Rab25 in Breast Cancer**

Arman Shahabi\(^1,2\), Behrooz Naghili\(^1\), Khalil Ansarin\(^3\), Maryam Montazeri\(^1\), Mehdi Dadashpour\(^5\), Nosratollah Zarghami\(^1,3\)*

**Abstract**

**Objective:** MicroRNAs (miRNAs) expression has deregulated in several cancer types including breast cancer (BC). The present study aims at investigating the role, mechanism, clinical value of let-7d and miR-185 in BC, and the possible correlation these miRNAs with Rab25. **Materials and Methods:** Tumor samples as well adjacent normal tissues (ANT) were acquired from fresh surgical specimens from 110 patients and the expression levels of let-7d, miR-185, Rab25, and snail were evaluated using real-time PCR. The immunohistochemical (IHC) process and western blot were done to detect the level of Rab25 and Snail protein expression in BC samples. **Results:** By comparing miRNAs expression profiles in clinical tissues of 110 patients using real-time PCR, let-7d, and miR-185 expression were dramatically downregulated in BC tissues (P < 0.05). Tumor size, stage, and lymph node metastasis were significantly related to miRNAs expression. Based on qRT-PCR and bioinformatics database analyses, we also recognized Rab25 as a possible target of miR-185 and let-7d. Rab25 expression was enhanced in BC cells and associated inversely with the expression level of mentioned miRNAs. qRT-PCR, immunohistochemistry, and western blot studies verified that Rab25 upregulation increased the levels of the snail, that key transcription factor of epithelial-mesenchymal transition (EMT). **Conclusion:** These findings demonstrated that let-7d and miR-185 inhibited EMT by targeting Rab25 expression in BC. Therefore, targeting the let-7d and miR-185/Rab25 interaction may offer new therapeutic opportunities for treating BC patients.

**Keywords:** Breast cancer- epithelial-mesenchymal transition- Let-7d- miR-185- Rab25

**Introduction**

Breast cancer (BC) is the most prevalent malignancy among all women, and it is identified to be one of the deadliest cancers (Chatran et al., 2018; Jafari-Gharabaghlu et al., 2018; Rasouli et al., 2020). Despite the noticeable progress in the diagnosis of the early BC stage, most of the patients diagnosed with BC (~90%) die as a result of metastasis (Hosseini et al., 2016). Metastasis occurs through multi-step processes such as local invasion, migration, transport, and colonization (Montazeri et al., 2017; Mellatyar et al., 2018). One of the crucial factors for metastatic dissemination of cancer is a developmental process termed epithelial-mesenchymal transition (EMT) (Brabletz et al., 2018; Bahmanpour et al., 2019). EMT is a phenomenon in which cells lose their epithelial features and exhibit the migratory phenotype of mesenchymal cells (Aiello et al., 2018; Mittal, 2018). Snail, a master EMT-transcription factor, plays essential roles in multiple stages of embryonic development and is positively associated with tumor metastasis. Recent researches have highlighted that microRNAs (miRNAs) are important factors in EMT and cancer cell metastasis (Mohammadian et al., 2017a; Mohammadian et al., 2017b; Sheervalilou et al., 2017a). MiRNAs are short non-coding RNAs (containing ~22 nucleotides) that control target genes by sequence-specific binding with their 3’-untranslated regions (UTRs) (Mohammadian et al., 2016a; Mohammadian et al., 2016b; Sheervalilou et al., 2017b). Several reports have indicated that miRNAs interfere in several physiological and pathological processes such as cell growth, apoptosis, angiogenesis, and metastasis (Mohammadian et al., 2016b; Sheervalilou et al., 2016; Sheervalilou et al., 2019). Additionally, investigations have demonstrated the role of miRNAs in the metastatic cascade of BC. For example, miR-132 prevents proliferation and invasion of BC cells by targeting FOXA1 (Wei et al., 2018). MiR-200c suppresses metastasis of BC by decreasing Foxf2 (Zhang et al., 2017). MiR-19b-1 inhibits angiogenesis and migration.
by targeting VEZF1 in BC (Yin et al., 2018b). Thus, miRNAs and their targets can be considered a complex network wherein they can affect metastatic BC. According to studies, reduced expression of let-7d and miR-185 has been detected in different types of cancers, such as colon, lung, gastric and ovarian cancer (García-Vázquez et al., 2018; Jiang et al., 2018). Let-7d belonging to the let-7 miRNA family has been recognized as a tumor suppressor miRNA, most likely by suppressing the expression of the high mobility group A2 (HMGAA2) or k-RAS (Wang et al., 2016). Furthermore, miR-185 regulates several types of cellular signaling that are necessary for the biological properties of tumor cells (Chai et al., 2017). However, the molecular mechanisms of these miRNAs in regulating EMT in BC remain largely unknown. Many studies showed that these miRNAs regulated various genes, which one of the most well-known ones is the Ras family. Rab25 (Ras-related protein Rab-25) is known as a molecular switch that is implicated in various biological processes and signaling pathways under normal and cancerous conditions (Mitra et al., 2016). In the current study, Rab25 was found to be a target gene of both let-7d and miR-185. Over-expression of Rab25 can counteract the effect of let-7d and miR-185, restore BC malignant phenotypes, and mediate its efficacy in BC progression that can be associated with Snail expression. Our findings suggest that let-7d, miR-185, and Rab25 might be appropriate tools for intervention development to improve BC diagnosis and treatment.

Materials and Methods

Tissue samples

Tumor samples as well adjacent normal tissues (ANT) were acquired from fresh surgical specimens from 110 patients who were treated at Noor-e-Nejat hospital, Tabriz, Iran from April 2016 to July 2018. The present research was ethically confirmed through the Ethics Committee of the Tabriz University of Medical Science (NO. IR.TBZMED.REC.1396.55). The clinicopathological data of these patients were collected with their signed written informed consent before inclusion in the current study. All fresh tissue specimens were gathered and instantly kept in liquid nitrogen at −80 °C. The histological studies were judged by two independent pathologists who were uninformed of the medical information of the corresponding patient.

RT-PCR analysis

Total cellular RNA was extracted from tissue samples according to the TRIzol reagent instructions (Invitrogen, USA). RNA was reverse-transcribed to complementary DNA (cDNA) by using QuantiTect cDNA synthesis kit (Qiagen, Germany) based on the manufacturers’ recommendations. RT-PCR with real-time quantitation was carried out by SYBR Green Master Mix and assessed on a Roche light cycler 96 (Germany) in triplicate. The sequence and details of the specific primers used to RT-PCR amplification of let-7d, miR-185, Rab25, snail, and GAPDH, as a reference gene, are listed in Table 1. PCR cycling conditions was as follow: 1 cycle at 95 °C for 5 min, followed by 40 cycles of 95 °C for 20 seconds and 72 °C for 30 seconds to 1 min. All samples were performed in triplicate and findings were computed by using the 2−∆∆CT method (Dadashpour et al., 2018).

Immunohistochemical staining

The immunohistochemical (IHC) process was done to detect the level of Rab25 and Snail protein expression. Tumor tissues were first fixed in 10% formalin-PBS buffer, embedded in paraffin, sectioned (4 μm thickness), and was mounted on glass slides. Then, diluted hydrogen peroxide (3%) was utilized to hinder the endogenous peroxidase activity. All the retrievals were performed in citrate buffer (pH 6–0) using microwave after that 1 h incubation with a mouse anti-Rab25 monoclonal antibody (1: 250, Abcam Inc, MA, USA) and rabbit anti-snail monoclonal antibody (1:100, Santa Cruz, Santa Cruz, CA, USA) overnight at 4°C. Negative controls were also obtained by the omission of specific primary antibodies. Then, tissue specimens were incubated with anti-mouse and the anti-rabbit secondary antibody, conjugated to HRP, at ambient temperature for 30 min. 3,3′-diaminobenzidine (DAB) tetrahydrochloride substrate was utilized for about 5 min to color development. Samples were counterstained with 0.1% hematoxylin and, finally, IHC stained slide investigated by a light microscope (Pilehvar-Soltanahmadi et al., 2017).

Immunohistochemical analysis

Assessment of IHC data was conducted by two different researchers who were blinded about clinical data of patients. The IHC results were stratified into 4 levels: 0, no staining; 1, weak; 2, moderate and 3, strong. The percent of the positive staining cells were scored as follows: 1 for <25%, 2 for 25–50%, 3 for 51–75%, and 4 for >75%. Final results were presented as follows: - (0 score, absent), + (1–4 score, weakly positive), ++ (5-8 score, moderately positive) and +++ (9–12 score, strongly positive). The scores of <5 was regarded as negative and the scores of ≥5 were defined as positive.

Western blotting

We performed western blot to identify Rab25 and Snail protein expression in BC samples. The protein content of tissue lysates was separated using 10% SDS-polyacrylamide gels and moved to polyvinyl difluoride membranes (Roche Diagnostics GmbH). Once being blocked with 5% defatted dry milk, the membranes were incubated with the primary antibodies against Rab25, Snail, and GAPDH at 4°C overnight. Afterward, the immunoreactive proteins were incubated with HRP-conjugated secondary antibodies (1:3,000, Razi Biotech Co, Tehran, Iran) at ambient temperature for 2 h and then visualized by using ECL detection Kit (Bio-Rad). The intensity of each western blot band was counted via ImageJ, version 1.44 software (National Institutes of Health, Bethesda, USA) and normalized to the respective GAPDH loading control (Sadeghi-Soureh et al., 2020).

Statistical analysis

The statistical data analysis was conducted applying the
Let-7d and miR-185 Impede EMT by Downregulating Rab25

SPSS 16.0 (Chicago, IL, USA) or Graph Pad Prism 6 (San Diego, CA, USA). Comparisons between the difference in means values among mRNA levels of BC and ANT samples were determined using the Mann–Whitney U test. One-way analysis of variance (ANOVA) was applied to assess the statistical differences in mRNA expression levels between the different histologic tumor grades. The statistical relationship among mRNA or protein levels of each group and clinicopathological features were analyzed using a Chi-Square, Student’s T-test or Mann-Whitney test, p-value <0.05 was considered to show a statistically significant difference.

Results

Let-7d and miR-185 expression was decreased in BC samples and was associated with clinicopathological criteria.

We investigated the potential effect of let-7d and miR-185 in BC development. We first examined the relative level of let-7d and miR-185 expression in 110 specimens of BC and ANT tissues. Let-7d and miR-185 were suppressed 4 and 1.8-fold, respectively, in BC compared to ANT (both P < 0.05) (Figures 1A and B).

Table 1. Sequences of let-7d, miR-185, Rab25, Snail and GAPDH Primers in Real-Time PCR

| Gene    | Primer sequences                                      |
|---------|-------------------------------------------------------|
| let-7d  | Forward: 5′-GCGAAGTGGTGTGCTGGAGG-3′<br>Reverse: 5′-CAGTGCGTGTCGCCAGGTT-3′ |
| miR-185 | Forward: 5′-TGCGGGTGCTCGCTTCGGCAGC-3′<br>Reverse: 5′-CCAGTGCAGGGTCCGAGGT-3′ |
| Rab25   | Forward: 5′-ACATTTCTCTCCGCTTCTGG-3′<br>Reverse: 5′-TGCCCACCACGCTCCATCATCTG-3′ |
| Snail   | Forward: 5′-CAATGCTCATCTGGAGAATCT-3′<br>Reverse: 5′-TTTCCCACTGCTCCATCTG-3′ |
| GAPDH   | Forward: 5′-TGTTGGCATCAATGATTGTTG-3′<br>Reverse: 5′-ACACCATGATTTCCGGTGCAAT-3′ |

Figure 1. Expression of let-7d and miR-185 was Downregulated in Breast Cancer (BC) Tissues. Quantitative PCR of let-7d and miR-185 in BC and adjacent normal specimens (ANT) (n=110). All samples were repeated 3 times and data were normalized to GAPDH. * p<0.05, ** p<0.01

Figure 2. Expression of Rab25 was up-Regulated in Breast Cancer (BC) Tissues. (A) Immunohistochemical staining of Rab25 expression in BC tissues. (a) 0 (no staining); (b) 1+ (weak); (c) 2+ (moderate); and (d) 3+ (strong). (B) Relative expression of Rab25 was detected by using the quantitative PCR in breast cancer and paired adjacent normal tissues (ANT), **p<0.01. (C) Rab25 protein expressions was determined by using the western blot assay. * p<0.05.
Table 2. Association between Clinicopathological Characteristics and mRNA Expression of let-7d, miR-185, Rab25 and Snail in 110 Patients with Breast Cancer

| Clinical pathological criteria | Rab25 expression (Mean ± SD) | P | Snail expression (Mean ± SD) | P | Let-7d expression (Mean ± SD) | P | miR-185 expression (Mean ± SD) | P |
|-------------------------------|------------------------------|---|-----------------------------|---|-------------------------------|---|-------------------------------|---|
| Age                           | 3.88 ± 1.57                  | 0.569 | 0.95 ± 0.30                | 0.807 | 0.19 ± 0.06                    | 0.31 | 0.32 ± 0.19                    | 0.563 |
| <50                           | 4.07 ± 1.74                  | 0.047 | 0.93 ± 0.38                | 0.059 | 0.17 ± 0.07                    | 0.11 | 0.30 ± 0.17                    | 0.063 |
| histological grade            |                              |     |                            |     |                               |     |                               |     |
| I                             | 3.46 ± 1.51                  | 0.047 | 1.01 ± 0.56                | 0.059 | 0.22 ± 0.08                    | 0.11 | 0.43 ± 0.07                    | 0.063 |
| II                            | 3.89 ± 1.56                  | 0.038 | 1.21 ± 0.75                | 0.11 | 0.18 ± 0.07                    | 0.38 | 0.38 ± 0.08                    | 0.063 |
| III                           | 4.99 ± 1.62                  | 0.047 | 1.32 ± 0.82                | 0.059 | 0.16 ± 0.08                    | 0.23 | 0.23 ± 0.16                    | 0.063 |
| PR                            | 3.97 ± 2.38                  | 0.047 | 0.96 ± 0.33                | 0.059 | 0.17 ± 0.07                    | 0.38 | 0.38 ± 0.08                    | 0.063 |
| Negative                      | 3.94 ± 1.54                  | 0.047 | 0.94 ± 0.31                | 0.059 | 0.19 ± 0.06                    | 0.40 | 0.40 ± 0.08                    | 0.063 |
| ER                            | 4.02 ± 1.73                  | 0.047 | 0.84 ± 0.16                | 0.059 | 0.19 ± 0.10                    | 0.40 | 0.40 ± 0.23                    | 0.063 |
| HER2                          | 3.93 ± 1.62                  | 0.047 | 0.95 ± 0.33                | 0.059 | 0.18 ± 0.06                    | 0.38 | 0.38 ± 0.08                    | 0.063 |
| Negative                      | 3.96 ± 1.63                  | 0.047 | 0.95 ± 0.33                | 0.059 | 0.19 ± 0.01                    | 0.39 | 0.39 ± 0.08                    | 0.063 |
| Positive                      | 3.59 ± 1.36                  | 0.047 | 0.73 ± 0.15                | 0.059 | 0.18 ± 0.03                    | 0.39 | 0.39 ± 0.09                    | 0.063 |
| Lymph node metastasis         | 3.51 ± 1.61                  | 0.047 | 0.93 ± 0.32                | 0.059 | 0.21 ± 0.11                    | 0.41 | 0.41 ± 0.15                    | 0.063 |
| Positive                      | 4.22 ± 1.57                  | 0.047 | 1.03 ± 0.33                | 0.059 | 0.17 ± 0.08                    | 0.32 | 0.32 ± 0.18                    | 0.063 |
| Stage                         | 3.48 ± 0.585                 | 0.021 | 0.967 ± 0.18               | 0.036 | 0.21 ± 0.15                    | 0.009 | 0.43 ± 0.15                    | 0.049 |
| 1                             | 3.69 ± 1.40                  | 0.021 | 0.894 ± 0.30               | 0.036 | 0.19 ± 0.07                    | 0.009 | 0.43 ± 0.15                    | 0.049 |
| 2                             | 3.88 ± 1.69                  | 0.021 | 1.14 ± 0.38                | 0.036 | 0.16 ± 0.08                    | 0.009 | 0.43 ± 0.15                    | 0.049 |
| 3                             | 4.18 ± 1.62                  | 0.021 | 0.902 ± 0.07               | 0.036 | 0.15 ± 0.07                    | 0.009 | 0.43 ± 0.15                    | 0.049 |
| Tumor size                    | 3.54 ± 1.51                  | 0.021 | 0.89 ± 0.27                | 0.036 | 0.21 ± 0.05                    | 0.009 | 0.43 ± 0.15                    | 0.049 |
| <20mm                         | 3.95 ± 1.50                  | 0.021 | 0.93 ± 0.32                | 0.036 | 0.18 ± 0.06                    | 0.009 | 0.43 ± 0.15                    | 0.049 |
| 20-49mm                       | 4.94 ± 1.94                  | 0.021 | 1.16 ± 0.48                | 0.036 | 0.15 ± 0.05                    | 0.009 | 0.43 ± 0.15                    | 0.049 |

Table 2 summarizes the correlation of let-7d and miR-185 with the clinicopathological criteria of the patients reviewed. In brief, no statistically significant difference was observed between let-7d and miR-185 and age, histological grade, expression of estrogen receptor (ER), progesterone receptor (PR), and HER-2. On the contrary, the results demonstrated that let-7d and miR-185 were significantly associated with tumor size, tumor stage, and lymph node metastasis. Our results indicated that downregulation of let-7d and miR-185 expression in BC tissues might cause metastasis.

Rab25 and Snail expression was increased in BC samples and was associated with clinicopathological criteria

The protein levels of Rab25 and Snail were detected by the IHC staining intensity in both BC and paired ANT tissues. In this case, Rab25 was expressed primarily in the cytoplasm, along with minimal expression in the nuclei of BC cells (Figure 2A). On the contrary, Snail staining was localized predominantly in the nucleus, and no positive staining was detected in the cytoplasm of BC cells. (Figure 3A). The positive expression rates of Rab25 and Snail expression in BC tissues were 82.7% (91/110) and 85.4% (94/110), respectively, is markedly higher than those of the relevant ANT (19%,21/110) and (35.4%, 39/110). To confirm IHC results, we also conducted quantitative-PCR to examine the Rab25 and Snail mRNA expression level in all BC and ANT cases. The level of Rab25 and Snail mRNA was higher in the BC group than in the ANT group (both P<0.001) (Figures 2Band 3B). Table 3 summarizes the associations of Rab25 and Snail protein expressions with various clinicopathological criteria. Our results indicated that Rab25 overexpression was associated with the tumor size (P = 0.021), lymph-node metastasis (P = 0.032), histological grade (P = 0.047) and pathological stage (P = 0.038) of BC. Besides, we detected a positive association between the Snail expression level and the tumor size (p=0.036), pathological stage (P=0.049), and lymph node metastasis (P =0.018). It is worth noting that similar results were found when the relationship was investigated between mRNA expression levels and clinicopathological parameters. Table 2 shows the data. The results showed that the Rab25 and Snail expression in BC tissues was significantly higher than that in ANT tissues. To confirm the results of IHC and qPCR analyses and to further investigate the effect of Rab25...
in induced EMT, we determined the expression levels of Rab25 and Snail by western blotting. Interestingly, our findings confirmed that the upregulation expression of Rab25 increased Snail to a certain extent (Figures 2C and 3C). As a result, these results strongly indicate that Rab25 promotes the EMT phenotype in BC cells through upregulation expression of Snail.

Rab25 expression is positively correlated with the Snail expression in BC tissues

The Spearman’s rank correlation coefficient was used to examine the relationship between Rab25 and snail protein expression levels. As Table 4 shows, Rab25 protein expression is positively correlated with the expression level of Snail. Out of sixty-seven Rab25 positive (++/+++ ) cases, fifty-two (77.6%) BC patients positively expressed

Figure 3. Expression of Snail was up-Regulated in Breast Cancer (BC) Tissues. (A) Immunohistochemical staining of the Snail expression in BC tissues. (a) 0 (no staining); (b) 1+ (weak); (c) +2 (moderate); and (d) +3 (strong). (B) Relative expression of Snail was detected by using the quantitative PCR in BC and paired adjacent normal tissues (ANT), ** p < 0.01. (C) Snail protein expressions was determined by using the western blot assay. * p<0.05.

Figure 4. Rab25 was the Direct Target of Both let-7d and miR-185. (A) Relative expression of let-7d and miR-185 compared to Rab25 expression in breast cancer (BC) tissues. (B) Scatter plot displaying the Spearman’s correlation between the let-7d and Rab25 expression in BC and adjacent normal tissues (ANT). (C) Scatter plot displaying the Spearman’s correlation between miR-185 and Rab25 expression in BC and ANT samples.
Snail (++/+++), while the co-expression of Rab25 and Snail was detected in two (25%) of the eight Rab25 positive cases in ANT tissues. Moreover, from sixteen BC samples with negative staining (−/+ ) for Snail, fourteen (87.5%) patients indicated IHC negative (−/+ ) for Rab25. Our finding revealed that the Rab25 and Snail expression levels were significantly associated with each other in all BC (r = 0.513, p = 0.011) and ANT samples (r= 0.263, p = 0.046).

Correlation between let-7d and miR-185 and Rab25 in BC tissues

Recent studies have reported that the reduction of some miRNAs was found to be related to higher levels of SNAIL expression. However, in our study, we did not observe a significant correlation between let-7d and miR-185 and Rab25 expression in BC tissues.

Table 3. Correlation between Clinicopathological Characteristics and Protein Expression of Rab25 and Snail in 110 Patients with Breast Cancer

| Clinical pathological criteria | RAB25 | Snail | P | Snail | P |
|------------------------------|-------|-------|---|-------|---|
| No. | Negative | Positive | | Negative | Positive | |
| Age | | | | | | |
| <50 | 75 | 15 | 60 | 9 | 66 | 0.136 | 0.384 |
| >50 | 35 | 9 | 26 | 7 | 28 | 0.041 | 0.038 |
| histological grade | | | | | | |
| I | 21 | 7 | 14 | 4 | 17 | 0.041 | 0.038 |
| II | 79 | 17 | 62 | 12 | 67 | 0.041 | 0.038 |
| III | 10 | 1 | 9 | 1 | 9 | 0.041 | 0.038 |
| PR | | | | | | |
| Negative | 34 | 13 | 21 | 16 | 18 | 0.416 | 0.208 |
| Positive | 76 | 22 | 54 | 11 | 51 | 0.416 | 0.208 |
| ER | | | | | | |
| Negative | 27 | 9 | 18 | 8 | 19 | 0.217 | 0.195 |
| Positive | 83 | 16 | 67 | 22 | 61 | 0.217 | 0.195 |
| HER2 | | | | | | |
| Negative | 99 | 23 | 76 | 21 | 78 | 0.753 | 0.881 |
| Positive | 11 | 3 | 8 | 2 | 9 | 0.753 | 0.881 |
| Lymph node metastasis | | | | | | |
| Negative | 46 | 20 | 26 | 13 | 33 | 0.009 | 0.001 |
| Positive | 64 | 4 | 60 | 3 | 61 | 0.009 | 0.001 |
| Stage | | | | | | |
| 1 | 16 | 7 | 9 | 4 | 12 | 0.015 | 0.046 |
| 2 | 72 | 17 | 55 | 11 | 61 | 0.015 | 0.046 |
| 3 | 18 | 2 | 16 | 1 | 17 | 0.015 | 0.046 |
| 4 | 4 | 1 | 3 | 1 | 3 | 0.015 | 0.046 |
| Tumor size | | | | | | |
| <20mm | 39 | 11 | 28 | 9 | 31 | 0.032 | 0.146 |
| 20-49mm | 61 | 12 | 49 | 5 | 55 | 0.032 | 0.146 |
| >50mm | 10 | 2 | 8 | 2 | 8 | 0.032 | 0.146 |

Table 4. Association between Rab25 and Snail Expression in Breast Cancer

| NO. | Rab25 expression | Snail expression | Correlation coefficient |
|-----|-----------------|-----------------|------------------------|
| -   | 11              | 65              | r= 0.513 (p = 0.011)   |
| +   | 5               | 15              | r= 0.263 (p = 0.046)   |
| ++  | 3               | 10              |                         |
| +++ | 0               | 4               |                         |

Arman Shahabi et al
expression of Rab proteins in different cancers (Shahabi et al., 2019; Yan et al., 2019). First, to ascertain the miRNAs targeting Rab25, we excavated target genes through two bioinformatics databases (miRDB and Target Scan) and provided a list of miRNAs targeting Rab25. Afterward, data mining techniques were performed, and miRNAs that significantly implicated the development in BC progression and metastasis phenotype were selected. According to the findings, we found that Rab25 might be one of the target genes of let-7d and miRNA-185. Moreover, the qPCR analysis showed that diminished expression of these miRNAs significantly downregulated the Rab25 expression in BC tissues rather than in ANT (Figures 4A and 4B). Correlation analysis of let-7d, miR-185, and Rab25 expression in BC tissues demonstrated an inverse relationship between declared miRNAs and Rab25 (Figure 4C). Overall, these results suggest that Rab25 is downregulated by let-7d and miRNA-185.

**Discussion**

miRNAs play vital roles in regulating the expression of cancer-related genes expression and are implicated in cancer development and progression (Kafshdooz et al., 2018; Tiwari et al., 2018; Norouzi et al., 2019; Sheervaliouli et al., 2020). Previous studies have indicated revealed that the let-7d level is strongly down-regulated downregulated in various cancer cells. Let-7d directly targets c-Myc, HMGAA2, CCL7, PBX3 and COL3A1 (Ramberg et al., 2011; Su et al., 2014; Ye et al., 2014), and so inhibits thereby inhibiting cancer cell invasion and metastasis. Another reports report found that miR-185 was able to regulate cellular proliferation, as well as DNA-damage response and repair (Wang et al., 2013; He et al., 2016). The relative expression of let-7d and miR-185 are lower in a variety of various cancer tissues. Besides, low expression of the mentioned miRNAs is related to large tumor size and advanced metastatic cancer (Wei et al., 2018). Consistent with previous reports (Fu et al., 2014; Wei et al., 2018), we discovered that let-7d and miR-185 expression was markedly reduced in BC tissues versus than in their paired ANTs, and proven both serve served as a tumor suppressor gene in BC. EMT is considered an important molecular event in tumor invasion and migration (Jolly et al., 2017). It is now well known that obviously, miRNAs could negatively regulate target genes via binding to 3′-UTR mRNAs, and let-7d and miR-185 downregulated downregulate the Rab25 expression. In conclusion, this study implied demonstrated that let-7d and miR-185 downregulation was associated with markedly significantly increased Rab25 expression, thereby reinforces reinforcing the BC invasion and metastasis via the snail-driven EMT. These results describe the mechanism underlying the tumor suppressor functions of let-7d and miR-185 and demonstrate that the signal pathway let-7d and miR-185/Rab25 might be a potential target for BC treatment.

In conclusion, this study demonstrated that let-7d and miR-185 downregulation was associated with significantly increased Rab25 expression, thereby reinforcing the BC invasion and metastasis via the snail-driven EMT. These results describe the mechanism underlying the tumor suppressor functions of let-7d and miR-185 and demonstrate that the signal pathway let-7d and miR-185/Rab25 may be a potential target for BC treatment.

**Acknowledgments**

The authors thank Dr. Ashraf Fakhrjou, Professor of Pathology, and Dr. Farshid Bozorgi for the pathological reevaluation of histological type, and histological grading.

**Funding**

This study was financially supported by grant No: 960205 of the Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

**Ethical approval**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Tabriz University of Medical Science (NO. IR.TBZMED.REC.1396.55) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Author’s contribution**

NZ and BN designed and directed the project; AS and VM processed the experimental data and performed the analysis, drafted the manuscript and designed the figures; NZ, BN and KA contributed to the final version of the manuscript. All authors provided critical feedback and helped to shape the research, analysis and manuscript.

**Informed consent**

Informed consent was obtained from all individual participants included in the study.

DOI:10.31557/APJCP.2021.22.1.305

*Let-7d and miR-185 Impede EMT by Downregulating Rab25*
Conflict of interest

The authors declare no conflicts of interest.

References

Aiello NM, Maddipati R, Norgard RJ, et al (2018). EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell, 45, 681-95. e4.

Bahmanpour Z, Sheeravaliou R, Choupani J, et al (2019). A new insight on serum microRNA expression as novel biomarkers in breast cancer patients. J Cell Physiol, 234, 19199-211.

Brabletz T, Kalluri R, Nieto MA, et al (2018). EMT in cancer. Nat Rev Cancer, 18, 128.

Chai Y, Yang X, Li Y, et al (2017). MicroRNA-185 overexpression sensitizes breast cancer cells to ionizing radiation: a potential therapeutic role in breast cancer. Int J Clin Exp Pathol, 10, 274-81.

Chatran M, Pilehvar-Soltanahmadi Y, Dadashpouro M, et al (2018). Synergistic anti-proliferative effects of metformin and silibinin combination on T47D breast cancer cells via hTERT and cyclin D1 inhibition. Drug Res, 68, 710-6.

Cheng KW, Lahad JP, Kuo W-I, et al (2004). The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med, 10, 1251-6.

Dadashpouro M, Pilehvar-Soltanahmadi Y, Mohammadi SA, et al (2018). Watercross-based electropulsion nanofibrous scaffolds enhance proliferation and stemness preservation of human adipose-derived stem cells. Artif Cells Nanomed Biotechnol, 46, 819-30.

Fu P, Du F, Yao M, et al (2014). MicroRNA-185 inhibits proliferation by targeting c-Met in human breast cancer cells. Exp Ther Med, 8, 1879-83.

Garcia-Vázquez R, Gallardo Rincón D, Ruiz-Garcia E, et al (2018). let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer. Oncol Rep, 39, 3086-94.

He M, Zhou W, Li C, et al (2016). MicroRNAs, DNA damage response, and cancer treatment. Int J Mol Sci, 17, 2087.

Hong L, Pan F, Jiang H, et al (2016). miR-125b inhibited epithelial–mesenchymal transition of triple-negative breast cancer by targeting MAP2K7. Oncol Rep, 39, 2369-76.

Hong L, Pan F, Jiang H, et al (2016). miR-125b inhibited epithelial–mesenchymal transition of triple-negative breast cancer by targeting MAP2K7. Oncol Rep, 39, 2369-76.

Jafari-Gharabaghlou D, Pilehvar-Soltanahmadi Y, Dadashpouro M, et al (2018). Combination of metformin and phenformin synergistically inhibits proliferation and hTERT expression in human breast cancer cells. Iran J Basic Med Sci, 21, 1167.

Jiang J, Liu H-L, Tao L, et al (2018). Let-7d inhibits colorectal cancer cell proliferation through the CST1/p65 pathway. Int J Oncol, 54, 550-552.

Jafari-Gharabaghlou D, Pilehvar-Soltanahmadi Y, Dadashpouro M, et al (2018). Combination of metformin and phenformin synergistically inhibits proliferation and hTERT expression in human breast cancer cells. Iran J Basic Med Sci, 21, 1167.

Kafshdooz L, Pourfathi H, Akbarzadeh A, et al (2018). The role of microRNAs and nanoparticles in ovarian cancer: a review. Artif Cells Nanomed Biotechnol, 46, 241-7.

Li W, Zhai L, Zhao C, et al (2015). miR-133 inhibits epithelial–mesenchymal transition by targeting metaldehyde in human breast cancer. Breast Cancer Res Treat, 150, 501-9.

Liu J, Zhou Y, Shi Z, et al (2016). microRNA-497 modulates breast cancer cell proliferation, invasion, and survival by targeting SMAD7. DNA Cell Biol, 35, 521-9.

Mellatyar H, Talaee S, Pilehvar-Soltanahmadi Y, et al (2018). Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art. Biomed Pharmacother, 102, 668-17.

Mitra S, Federico L, Zhao W, et al (2016). Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget, 7, 40252.

Mittal V (2018). Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol-Mech Dis, 13, 395-412.

Mohammadian F, Abhari A, Dariushehjad H, et al (2016a). Effects of chrysín-PLGA-PEG nanoparticles on proliferation and gene expression of miRNAs in gastric cancer cell line. Iran J Cancer Prev, 9, e4190.

Mohammadian F, Abhari A, Dariushehjad H, et al (2016b). Upregulation of Mir-34a in AGS gastric cancer cells by a PLGA-PEG-PLGA chrysín nano formulation. Asian Pac J Cancer Prev, 16, 8259-63.

Mohammadian F, Pilehvar-Soltanahmadi Y, Alipour S, et al (2017a). Chrysín alters microRNAs expression levels in gastric cancer cells: possible molecular mechanism. Drug Res, 67, 509-14.

Mohammadian F, Pilehvar-Soltanahmadi Y, Mofarah M, et al (2016c). Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysín-loaded PLGA-PEG nanoparticles. Artif Cells Nanomed Biotechnol, 44, 1972-8.

Mohammadian F, Pilehvar-Soltanahmadi Y, Zarghami F, et al (2017b). Upregulation of miR-9 and Let-7a by nanoencapsulated chrysín in gastric cancer cells. Artif Cells Nanomed Biotechnol, 45, 1201-6.

Montazeri M, Pilehvar-Soltanahmadi Y, Mohaghegh M, et al (2017). Antiproliferative and apoptotic effect of dengrosomal curcumin nanoformulation in P53 mutant and wide-type cancer cell lines. Curr Med Chem Anticancer Agents, 17, 662-73.

Norouzi M, Yasmineh S, Montazeri M, et al (2019). Recent advances on nanomaterials-based fluorimetric approaches for microRNAs detection. Mater Sci Eng C Mater Biol Appl, 104, 110007.

Pilehvar-Soltanahmadi Y, Nouri M, Martino MM, et al (2017). Cytoprotection, proliferation and epidermal differentiation of adipose tissue-derived stem cells on emu oil based electropulsion nanofibrous mat. Exp Cell Res, 357, 192-201.

Ramberg H, Alshbib A, Berge V, et al (2011). Regulation of PBX3 expression by androgen and Let-7d in prostate cancer. Mol Cancer, 10, 50.

Rasouli S, Montazeri M, Mashayekhi S, et al (2020). Synergistic anticancer effects of electropulsion nanofiber-mediated codelivery of Curcumin and Chrysín: Possible application in prevention of breast cancer local recurrence. J Drug Deliv Sci Technol, 55, 101402.

Sadeghi-Soureh S, Jafari R, Gholikhani-Darbroud R, et al (2020). Potential of Chrysín-loaded PCL/gelatin nanofibers for modulation of macrophage functional polarity towards anti-inflammatory/pro-regenerative phenotype. J Drug Deliv Sci Technol, 58, 101802.

Shahabi A, Naghli B, Ansarin K, et al (2019). The relationship between microRNAs and Rab family GAPsases in human cancers. J Cell Physiol, 234, 12341-52.

Sheeravaliou R, Ansarin K, Fekri Aval S, et al (2016). An update on sputum Micro RNA s in lung cancer diagnosis. Diagn Cytopathol, 44, 442-9.

Sheeravaliou R, Khamaneh AM, Sharifi A, et al (2017a). Using miR-10b, miR-1 and miR-30a expression profiles of bronchoalveolar lavage and sputum for early detection of non-small cell lung cancer. Biomed Pharmacother, 88, 1173-82.

Sheeravaliou R, Lotfi H, Shiravaliou M, et al (2019). Circulating MiR-10b, MiR-1 and MiR-30a expression profiles in lung cancer: Possible Correlation with Clinico-pathologic Characteristics and Lung Cancer Detection. Int J Mol Cell Med, 8, 118.

Sheeravaliou R, Shahraki O, Hasanifard L, et al (2020). Electrochemical Nano-biosensors as Novel Approach for...
Let-7d and miR-185 Impede EMT by Downregulating Rab25

the Detection of Lung Cancer-related MicroRNAs. *Curr Mol Med*, 20, 13-35.

Sheervalilou R, Shirvaliloo S, Fekri Aval S, et al (2017b). A new insight on reciprocal relationship between microRNA expression and epigenetic modifications in human lung cancer. *Tumor Biol*, 39, 1010428317695032.

Su B, Zhao W, Shi B, et al (2014). Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7. *Mol Cancer*, 13, 206.

Tang C-P, Zhou H-J, Qin J, et al (2017). MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer. *Oncol Rep*, 38, 3144-52.

Tiwari A, Mukherjee B, Dixit M (2018). MicroRNA key to angiogenesis regulation: microRNA biology and therapy. *Curr Cancer Drug Targets*, 18, 266-77.

Wang B, Yang Z, Wang H, et al (2015). MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A. *Am J Cancer Res*, 5, 2719.

Wang J, He J, Su F, et al (2013). Repression of ATR pathway by miR-185 enhances radiation-induced apoptosis and proliferation inhibition. *Cell Death Dis*, 4, e699-e.

Wang Y, Le Y, Xue J-Y, et al (2016). Let-7d miRNA prevents TGF-β1-induced EMT and renal fibrogenesis through regulation of HMGA2 expression. *Biochem Biophys Res Commun*, 479, 676-82.

Wei Y, Liu G, Wu B, et al (2018). Let-7d inhibits growth and metastasis in breast cancer by targeting Jab1/Cops5. *Cell Physiol Biochem*, 47, 2126-35.

Xue Y, Xu W, Zhao W, et al (2017). miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4. *Biomed Pharmacother*, 86, 426-33.

Yan L, Wu K, Du F, et al (2019). miR-384 suppressed renal cell carcinoma cell proliferation and migration through targeting RAB23. *J Cell Biochem*, 120, 1420-6.

Ye F, Tang H, Liu Q, et al (2014). miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. *J Transl Med*, 12, 1-10.

Yin C, Mou Q, Pan X, et al (2018a). MiR-577 suppresses epithelial-mesenchymal transition and metastasis of breast cancer by targeting Rab25. *Thorac Cancer*, 9, 472-9.

Yin R, Guo L, Gu J, et al (2018b). Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis. *Int J Biochem Cell Biol*, 97, 43-51.

Zhai L, Ma C, Li W, et al (2016). miR-143 suppresses epithelial–mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5. *Mol Carcinog*, 55, 1990-2000.

Zhang T, Wan J, Liu J, et al (2017). MiR-200c inhibits metastasis of breast tumor via the downregulation of Foxf2. *Genet Mol Res*, 16, gmr16038971.

Zhao M, Ang L, Huang J, et al (2017). MicroRNAs regulate the epithelial–mesenchymal transition and influence breast cancer invasion and metastasis. *Tumor Biol*, 39, 1010428317691682.